

HIGHLIGHTS

AEDV

en la 6ª edición del SPIN

Skin Inflammation & Psoriasis
International Network Congress

PARIS
25-27
abril

PSORIASIS

Álvaro González Cantero

Servicio de Dermatología, Complejo
Hospitalario de Toledo

Iniciativa científica de:




PSORIASIS

- “Educational course on psoriasis” (chair: Estaban Dauden y Luigi Naldi)
 - Genetics/Pathogenesis (Paola Di Meglio)
 - Comorbidities (Tiago Torres)
 - Topical therapy (Rolland Gyulai)
 - Non-biological systemic therapy (Paola Cardenas)
 - Biologic systemic therapy (David Moreno)
- Discussed E-Posters:
 - Parkinson´s disease and psoriasis
 - Alzheimer´s disease and psoriasis

“GENETICS/PATHOGENESIS (PAOLA DI MEGLIO)

- Genetics of Psoriasis pre-GWAS:
 - Psoriasis heredability: 66%
 - Gene/loci: **10** (PSORS1, 6p21, HLA-C9)
- The 21st century genoma revolution:
 - GWAS / Disease-associated SNPs.
 - Genetics of Psoriasis in 2019: **63** susceptibility loci in Europeans.


GENETICS OF PSORIASIS IN 2019:



GENETICS OF PSORIASIS IN 2019:

- New challenges -> Biomarkers.
- One size DOES NOT fit all.
- Personalized medicine.
- Genetics of response to biologics: 21 studies.


GENETICS OF PSORIASIS IN 2019:



TOPICAL THERAPY (ROLLAND GYULAI)

- Few promising new developments.
- Topical tofacitinib (JAK inhibitor) – modest efficacy.
- Roflumilast and TAK-084 (topical PDE4 inhibitors) -> reduce skin infiltrate thickness in psoriasis.
- Tapinarof cream-promising phase 2 results.

TAPINAROF CREAM-PROMISING PHASE 2 RESULTS.



THE RISK OF PARKINSON'S DISEASE IN PATIENTS WITH PSORIASIS: A NATIONWIDE POPULATION-BASED COHORT STUDY

J.H. Lee, K. Han, H.Y. Gee

- **Background:** The association between psoriasis and Parkinson's disease is still not established.
- **Objectives:** The aim of this study was to determine the incidence rates and risk factors of Parkinson's disease in patients with psoriasis.

THE RISK OF PARKINSON'S DISEASE IN PATIENTS WITH PSORIASIS: A NATIONWIDE POPULATION-BASED COHORT STUDY

J.H. Lee, K. Han, H.Y. Gee

- **Methods:** This was a nationwide population-based cohort study. The data from patients with psoriasis (N = 548,327; age \geq 20 years; males, 53.32%; females, 46.68%) and age- and sex-matched control subjects (N = 2,741,635) without psoriasis were analyzed in this study.

THE RISK OF PARKINSON'S DISEASE IN PATIENTS WITH PSORIASIS: A NATIONWIDE POPULATION-BASED COHORT STUDY

J.H. Lee, K. Han, H.Y. Gee

- In conclusion, we observed a significant increase in the incidence of PD in patients with psoriasis compared with that in patients without psoriasis and a reduction in the risk of PD in patients receiving systemic treatment for psoriasis.

ALZHEIMER'S DISEASE RISK IN PATIENTS WITH PSORIASIS: A NATIONWIDE POPULATION-BASED COHORT STUDY

J.H. Lee, S.-H. Lee, K. Han, M. Kim

- **Background:** Alzheimer's disease (AD), the most common cause of dementia, is a chronic neurodegenerative disease. Although some studies have reported an association between inflammatory skin conditions such as rosacea and seborrheic dermatitis and neurodegenerative disease, no large-scale studies have explored the possible relationship between AD and psoriasis.
- **Objectives:** We investigate to determine the risk of AD in patients with psoriasis

ALZHEIMER'S DISEASE RISK IN PATIENTS WITH PSORIASIS: A NATIONWIDE POPULATION-BASED COHORT STUDY

J.H. Lee, S.-H. Lee, K. Han, M. Kim

Discussion

Psoriasis was associated with an increased risk of AD, with stronger associations observed in middle-aged than in elderly patients. Patients receiving systemic treatment had a significantly lower risk of AD than the control group or patients not receiving systemic treatment. These findings provide a better understanding of the role of inflammation in the pathogenesis of AD, suggesting a potential target for systemic anti-inflammatory drugs for the treatment of AD.



GRACIAS

Iniciativa científica de:

